Barinthus Biotherapeutics’ (BRNS) Buy Rating Reiterated at HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 323.69% from the stock’s current price.

Several other equities analysts have also recently weighed in on BRNS. William Blair reaffirmed an “outperform” rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Barclays dropped their target price on Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a report on Thursday, June 13th. Finally, Alliance Global Partners decreased their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock opened at $1.18 on Thursday. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10. The stock has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.87. The stock has a market capitalization of $46.52 million, a PE ratio of -0.66 and a beta of -0.53.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). Research analysts forecast that Barinthus Biotherapeutics will post -1.71 EPS for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several hedge funds have recently modified their holdings of the company. M&G Plc bought a new position in shares of Barinthus Biotherapeutics in the second quarter valued at approximately $7,276,000. Alphabet Inc. bought a new position in Barinthus Biotherapeutics in the 2nd quarter valued at $2,119,000. DC Funds LP purchased a new stake in shares of Barinthus Biotherapeutics during the 1st quarter valued at $1,528,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Barinthus Biotherapeutics during the 1st quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. bought a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth $32,000. Institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.